Ga Hee Ha;Jeong-Min Kim;Joo Heon Kim;Cheol-Hee Kim;Soo Young Jun;In-Sung Song;Nam-Soon Kim;Jin-Man Kim;So-Young Jeong;Hyun-Taek Kim
发明人:
Nam-Soon Kim,In-Sung Song,Cheol-Hee Kim,Ga Hee Ha,Hyun-Taek Kim,So-Young Jeong,Jeong-Min Kim,Joo Heon Kim,Jin-Man Kim,Soo Young Jun
申请号：
US13579256
公开号：
US08703732B2
申请日:
2011.04.01
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.
